安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- FORAGER-1: A Study of LOXO-435 (LY3866288) in . . . - Lilly Trials
LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene) Answer a few questions to see if you meet key criteria for this study ≥18 years Bladder Cancer, Advanced Solid Tumors What the trial is testing?
- ASCO GU 2025: A First-in-Human Phase 1 Study of LY3866288 (LOXO-435), a . . .
Dr Gopa Iyer presented the initial results of FORAGER-1, a first-in-human phase I study of LY3866288 (LOXO-435) in advanced solid tumors with FGFR3 alterations LY3866288 is an oral, potent, highly isoform-selective, small molecule FGFR3 inhibitor designed to limit off-target toxicities
- Bladder Cancer UCLA Clinical Trial | FORAGER-1: A Study . . . - UCLA Health
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer
- A Phase 1a Study of LOXO-435 in People with Advanced Solid Tumors . . .
The purpose of this study is to find the highest dose of the investigational drug LOXO-435 that can be given safely in people with advanced solid tumors that have come back or continued to grow despite treatment and contain a change in the FGFR3 gene
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer . . .
Summary: The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer . . .
Trial Objectives and Outline This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC)
- CLINICAL TRIAL NCT05614739 - UChicago Medicine
FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations
- Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic . . .
FORAGER-1 is a phase 1 trial of LY3866288, or LOXO-435 This is an FGFR3 isoform-specific inhibitor It's very potent It's very selective for FGFR3 instead of FGFR 1 and 2
|
|
|